ALX Oncology
Manufacturing · California, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
323 Allerton Ave, South San Francisco, C...Phone Number
(650) 466-7125Website
www.alxoncology.comRevenue
$15.6 MillionStock Symbol
ALXOIndustry
ZI Rank: 1
Signal Type
Jan
Feb
Mar
Apr
May
Jun
ZI Rank
3
1
1
1
1
1
About ALX Oncology
ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company, focuses on developing therapies for cancer patients in the United States. The company's lead product candidate is Evorpacept, a CD47 blocking therapeutic biologic in development as a combination therapy with other anti-cancer agents, including ASPEN-06, under Phase 2 clinical study for treating Gastric/GEJ cancer; ASPEN-07, under Phase 1 clinical study for treating urothelial cancer; and ASPEN-03 and ASPEN-04, both under Phase 2 clinical study for treating head and neck squamous cell carcinoma. It also has collaboration agreement for Evorpacept combination programs comprising Jazz Pharmaceuticals plc for zanidatamab, under Phase 1 trial for the treatment of breast cancer and other solid tumors; Quantum Leap Healthcare collaborative with an ADC, fam-trastuzumab deruxtecan-nxki, under Phase 1 trial for the treatment of patients with breast cancer; MD Anderson Cancer Center with rituximab and lenalidomide for the treatmRead more
ALX Oncology Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is ALX Oncology your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Check if ALX Oncology has recently received funding, and reach out quickly before it becomes old news!
Website visits: Recent activity has been detected on your website
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Check out if ALX Oncology is spiking on competitors!
ALX Oncology, which may be a good buyer, showed buying intent in Masked Content Topic
Funding: Get notified immidiatlly once ALX Oncology has new funding data
Click to see if ALX Oncology had a recent Job posting/layoffs
Earning: See what the market has to say on ALX Oncology recently announced quarterly report
Product Launch: Get notified when ALX Oncology launches new products
Congratulate Masked Content for being promoted to Masked Content at ALX Oncology
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find more new buyers
Compare Similar Companies to ALX Oncology
Compare insights from companies similar to ALX Oncology, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
ALX Oncology is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
ALX Oncology is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about ALX Oncology.
ALX Oncology financials insights
Gather financial insights about ALX Oncology, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2015
Series A
$36M
2020
Series C
$105M
Stock Offering
$185.7M
2022
Debt
$100M
2026
Unspecified
$150M
ALX Oncology Tech Stack
A closer look at the technologies used by ALX Oncology
See more technologies
Most Recent Scoops
Project
ALX Oncology has planned an interim analysis of approximately 80 patients from its ASPEN-09 trial for mid-2026, at which point the company intends to engage with the FDA to discuss a Phase III design of evorpacept plus trastuzumab plus chemotherapy versus trastuzumab plus chemotherapy in CD47-high HER2-positive breast cancer patients.
Pharmaceuticals, Clinical Operations
Project
ALX Oncology has planned a safety update for ALX2004 later in the current year, covering data on 10 to 15 or more patients with a balanced mix across four tumor types, with key endpoints including absence of high-rate interstitial lung disease, manageable gastrointestinal toxicity, absence of significant skin or rash toxicity, and early signs of antitumor activity.
Medical Research, Pharmaceuticals, Clinical Operations
Project
ALX Oncology has reported clinical data for evorpacept in a randomized HER2-positive gastric cancer setting, demonstrating approximately a 40% delta in overall response rate versus control, a progression-free survival hazard ratio of approximately 0.4, and a median progression-free survival exceeding 2 years. In CD47-high patients, the overall response rate reached 65% in combination with zanidatamab in second- and third-line HER2-positive gastric cancer.
Medical Research, Clinical Operations
Project
plans to move into cohort backfill and expansion for ALX2004 following the initial safety readout, prioritizing second-line head and neck squamous cell carcinoma and second-line non-small cell lung cancer settings, with a goal of achieving proof-of-concept data in relevant patient populations by 2026.
Project
Pharmaceuticals
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding ALX Oncology
Sign Up For FreeTo access detailed company insights
ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company, focuses on developing therapies for cancer patients in the United States. The company's lead product candidate is Evorpacept, a CD47 blocking therapeutic biologic in development as a combination therapy with other anti-cancer agents, including ASPEN-06, under Phase 2 clinical stu... Read More
